| West Virginia Hospice 6 Hartman Plaza, Buckhannon, WV, 26201 | |
| (304) 473-6800 |
News Archive
QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Now that scientists have learned so much about aging through laboratory studies, it's time to translate those findings into medicines that can benefit our aging population. That was the message delivered by a panel of 10 preeminent aging experts that included Jan Vijg, Ph.D., chair of genetics and the Lola and Saul Kramer Chair in Molecular Genetics at Albert Einstein College of Medicine of Yeshiva University.
Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.
A thickening of the brain cortex associated with regular meditation or other spiritual or religious practice could be the reason those activities guard against depression - particularly in people who are predisposed to the disease, according to new research led by Lisa Miller, professor and director of Clinical Psychology and director of the Spirituality Mind Body Institute at Teachers College, Columbia University.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 4 days ago
| Name | West Virginia Hospice |
|---|---|
| Location | 6 Hartman Plaza, Buckhannon, West Virginia |
| Hospice ID | 511516 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Other |
| Profit Type | FOR PROFIT |
| SSA county code | 480 |
News Archive
QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Now that scientists have learned so much about aging through laboratory studies, it's time to translate those findings into medicines that can benefit our aging population. That was the message delivered by a panel of 10 preeminent aging experts that included Jan Vijg, Ph.D., chair of genetics and the Lola and Saul Kramer Chair in Molecular Genetics at Albert Einstein College of Medicine of Yeshiva University.
Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.
A thickening of the brain cortex associated with regular meditation or other spiritual or religious practice could be the reason those activities guard against depression - particularly in people who are predisposed to the disease, according to new research led by Lisa Miller, professor and director of Clinical Psychology and director of the Spirituality Mind Body Institute at Teachers College, Columbia University.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 4 days ago
| NPI Number | 1205250032 |
| Organization Name | Lhcg Lii, Llc |
| Address | 6 Hartman Plz Buckhannon, West Virginia, 26201 |
| Phone Number | (304)473-6800 |
News Archive
QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Now that scientists have learned so much about aging through laboratory studies, it's time to translate those findings into medicines that can benefit our aging population. That was the message delivered by a panel of 10 preeminent aging experts that included Jan Vijg, Ph.D., chair of genetics and the Lola and Saul Kramer Chair in Molecular Genetics at Albert Einstein College of Medicine of Yeshiva University.
Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.
A thickening of the brain cortex associated with regular meditation or other spiritual or religious practice could be the reason those activities guard against depression - particularly in people who are predisposed to the disease, according to new research led by Lisa Miller, professor and director of Clinical Psychology and director of the Spirituality Mind Body Institute at Teachers College, Columbia University.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.1 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.4 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 97.1 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 99.4 | 97.3 |
| Patients who got timely treatment for shortness of breath | 95.8 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 95.0 | 93.3 |
News Archive
QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Now that scientists have learned so much about aging through laboratory studies, it's time to translate those findings into medicines that can benefit our aging population. That was the message delivered by a panel of 10 preeminent aging experts that included Jan Vijg, Ph.D., chair of genetics and the Lola and Saul Kramer Chair in Molecular Genetics at Albert Einstein College of Medicine of Yeshiva University.
Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.
A thickening of the brain cortex associated with regular meditation or other spiritual or religious practice could be the reason those activities guard against depression - particularly in people who are predisposed to the disease, according to new research led by Lisa Miller, professor and director of Clinical Psychology and director of the Spirituality Mind Body Institute at Teachers College, Columbia University.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 4 days ago
| Home Health Aides | 3 |
| Counselors | 1 |
| Licensed Practical or Vocational Nurses | 4 |
| Medical Social Workers | 1 |
| Physicians | 1 |
| Registered Nurses | 6 |
| Other Personnel | 3 |
| Total Employees | 19 |
|---|
News Archive
QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Now that scientists have learned so much about aging through laboratory studies, it's time to translate those findings into medicines that can benefit our aging population. That was the message delivered by a panel of 10 preeminent aging experts that included Jan Vijg, Ph.D., chair of genetics and the Lola and Saul Kramer Chair in Molecular Genetics at Albert Einstein College of Medicine of Yeshiva University.
Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.
A thickening of the brain cortex associated with regular meditation or other spiritual or religious practice could be the reason those activities guard against depression - particularly in people who are predisposed to the disease, according to new research led by Lisa Miller, professor and director of Clinical Psychology and director of the Spirituality Mind Body Institute at Teachers College, Columbia University.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 4 days ago
| Others | 7 |
| Total Volunteers | 7 |
|---|
News Archive
QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Now that scientists have learned so much about aging through laboratory studies, it's time to translate those findings into medicines that can benefit our aging population. That was the message delivered by a panel of 10 preeminent aging experts that included Jan Vijg, Ph.D., chair of genetics and the Lola and Saul Kramer Chair in Molecular Genetics at Albert Einstein College of Medicine of Yeshiva University.
Amid growing concerns over the long-term sustainability of access to affordable HIV/AIDS drugs, UNAIDS, WHO and the U.N. Development Program on Tuesday released a policy brief advising countries on how they can successfully use rules written into the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights to lower the cost of and increase access to HIV treatment, Intellectual Property Watch reports.
A thickening of the brain cortex associated with regular meditation or other spiritual or religious practice could be the reason those activities guard against depression - particularly in people who are predisposed to the disease, according to new research led by Lisa Miller, professor and director of Clinical Psychology and director of the Spirituality Mind Body Institute at Teachers College, Columbia University.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.
› Verified 4 days ago
| West Virginia Hospice Location: 6 Hartman Plaza, Buckhannon, West Virginia, 26201 Phone: (304) 473-6800 |